Cefprozil for Oral Suspension 250 mg/5 mL, Non-fasting

Summary

The objective of this study is to compare the relative bioavailability of cefprozil for oral suspension 250 mg/5 mL (TEVA Pharmaceuticals USA) with that of CEFZIL® for Oral Suspension 250 mg/5 mL (Bristol-Myers Squibb) in healthy, non-smoking adults under non-fasting conditions.

Timeline

Start

2004-05

Primary completion

2004-05

Completion

2004-05

Outcome

Met primary endpoint

registry Ratio of the T/R geometric mean x 100 89.2 (90% CI 86.2 to 92.2) NCT00835354 ↗

registry Ratio of the T/R geometric mean x 100 90.5 (90% CI 88.9 to 92.1) NCT00835354 ↗

registry Ratio of the T/R geometric mean x 100 90.7 (90% CI 89.1 to 92.3) NCT00835354 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CEFPROZIL ANHYDROUS, (E)-	Small molecule	250 mg	Oral

Indications

No indication recorded.